Akers Biosciences Share Discussion Threads

[wigwammer] 02/3/2017 12:16

Yes, sales were up a lot. +50%.Does it make sense to compare 2015 unit sales to 2016 unit sales achieved at an 80% price premium?

[mcmather] 02/3/2017 10:00

wigwammer. didn't they double the sale price of each device from Q1 2016? It was certainly a significant increase.

Say they increased the price by 80%, using the figure quoted of $1.4m * 80% = $2.52m; ie revenue was up but unit sales would appear to have reduced on that basis?

[wigwammer] 02/3/2017 08:01

"Either way, if you take away the Chinese order which has been in the pipeline for a number of years now, the sales of the signature product, PIFA HIT, flat-lined at best elsewhere (ie the US) in 2016."Appreciate your thoughts but this is not correct. Pifa hep sales 2016 = $2.6m. Minus china order = $2.1m vs $1.4m 2015. Pifa hit sales grew circa 50%. They did not flatline. True, you never get honey out of a wasp. But contrary to earlier suggestion, they did get the issue money. I'm interested at £1. The smitten are on record buying at £5+, got burnt, and are now evidently a bit bitter about it.

[norbus] 01/3/2017 14:37

mcm

You never get honey out of a wasp; but don't tell that to the smitten

[mcmather] 01/3/2017 00:37

YE 2015 $2,115,050.

Q1 2016 $738,023.
Q2 2016 $956,487.
Q3 2016 $613,198
Q4 2016 $692,000 circa.
Total $3m approx.

H1 2016 included $505,380 from the Chinese order. Deduct this from the $3m (total 2016) leaves around $380k.

Revenue for 2016 essentially revolved around PIFA HIT. Q1 2016 results included the comment that "Demand for PIFA Heparin/PF4 Rapid Assay withstood the new increased pricing schedule implemented in Q1, reflecting clinical dependence on the test from existing customers".

Not 100% on this but was the "increased pricing schedule" for the device just shy of 100%?

Either way, if you take away the Chinese order which has been in the pipeline for a number of years now, the sales of the signature product, PIFA HIT, flat-lined at best elsewhere (ie the US) in 2016.

Appreciate that Gormally might still get a grip here - the wellness / disposal breath test market could still be interesting - but the evidence currently available suggests that the results for shareholders is no different to that of Mr Mitty.

[mcmather] 01/3/2017 00:22

wigwammer re #3391; in the Q3 conference call Gormally said he "anticipates" receiving the remainder of the Chinese order in Q4 although there was no conviction in what he was saying at this time; around 11mins 45 secs.

The Nasdaq price at the time of the conference call had been trading well over $3 for 3 months plus.

The recent TU states "NovoTek has conveyed that it has faced additional regulatory hurdles for pricing in China...NovoTek has informed the Company that it now has key opinion leaders positioned across 90 Chinese hospitals in 12 provinces and that it expects high end-user demand once pricing approvals have been obtained".

The latest RNS 16 Feb 2017 re the Wellness patent includes "In addition to targeting professionals, Akers Wellness(TM) intends to start marketing OxiChek(TM) through direct-to-consumer channels during 2017. This will include a television marketing campaign"; ie outlay / expense.

A large part of Gormally's remit is to look after the interests of shareholders.

The conference call was 14 Nov 2016 and the placing was just 8 weeks later. It must have been inevitable that a placing was necessary and also that funds would be required for programmes (eg Wellness) going in to 2017.

Even at a 20% discount to the nasdaq share price at the time (call it $3.30) would have achieved a placing at $2.60.

Obviously, there is the possibility that the actual figure ($1.20) was all that those who participated were prepared to pay; ie no great confidence in AKR / AKER? The obvious alternative being that those that did partake in the placing have benefited significantly at the expene of the shareholders on board prior the issue?

Gormally might not be as careless as Wally but the end result is, ultimately, still the same for shareholders.

[wigwammer] 27/2/2017 17:23

It appears they collected the issue money, despite fears to the contrary.Strange that the fear of no collection (as opposed to the fact of collection) is considered noteworthy on this unbiased and highly informative board.

[norbus] 27/2/2017 12:21

mcm

where is China with 2/3rd of the Qtr gone

[wigwammer] 01/2/2017 13:10

Record pifa sales in h2, coupled with a significantly lower cost base ($4.6m vs $7m cash breakeven sales rate) and a near historic low valuation - probably never been a better time to buy.

[norbus] 01/2/2017 07:37

expected profit warning

Approximately $0.5 million in sales of these products to China were recorded in 2016. This was significantly below expectations of sales to China in the period as the balance of the $2.5 million order from NovoTek Therapeutics Inc. ("NovoTek"), the Company's exclusive distributor for these products in China, announced in March 2016, has not yet been released.

Sad

Best salvage as it stands is to sell the flagship product and then file for a class action against the directors and professionals

[wigwammer] 22/1/2017 09:29

"If they needed funding - which they clearly did"Perhaps they didn't know if the large Chinese order would materialise. With another $1.5m-$2m in hand perhaps they would not have needed to ask for the money, or could at least have scaled it back.

[mcmather] 21/1/2017 09:32

The initial S3 form submitted 24 October 2016 included "On October 18, 2016, the last reported sale price of our common stock on the Nasdaq Capital Market was $3.30 per share".

If they needed funding - which they clearly did - then why did Gormally not simply get the funds secured at that time when the share price had been trading above $3 for around 3 months?

Even with, say, a hefty 20% discount they could still probably have placed at around $2.50.

The proposed placing at $1.20 suggests to me that he is either a "friend of Wally", looking after persons other than current shareholders or that there is little appetite for the stock (ie belief in what he / the management are doing); was it determined whether any of the management took part in the offering?

[wigwammer] 20/1/2017 11:32

Sure.In other news, mid price now down to the usd quote level, and around the issue price.Seems to be a few buyers coming in.

[wigwammer] 19/1/2017 23:50

Tbh saying that sort of thing on a chat board doesn't definitively define anyone, and I feel bad about suggesting it.But it's still a stupid thing to say.I'll lose all my money here but I won't get dragged into that sh1te.

[qazwsxedc69] 19/1/2017 15:36

Classy Norbus, Real CLASSY.

[norbus] 17/1/2017 08:24

Must be still collecting the issue money; Does not feel right

[wigwammer] 16/1/2017 12:03

Lots of words, vaguely pertaining to the (endlessly repeated) point that you don't like Dr Akers.Beyond that, as a previous poster suggested, nothing of much use.

[norbus] 16/1/2017 11:06

Nobody throws good money after bad

unless they were great stock pickers like Neil Woodford who is looking to recruit; With a closing date last Thursday, I suppose they are cutting the application due to massive over subscription and attention to the-inauguration balls invitations on offer to The Akers